Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levotofisopam SCHEMBL5431173 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Tofisopam SCHEMBL29832594 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Dextofisopam SCHEMBL8086913 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Dextofisopam SCHEMBL29376877 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Tofisopam SCHEMBL43522 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Tofisopam SCHEMBL4585183 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Tofisopam SCHEMBL8086894 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| SCHEMBL5426026 | 0.94 | PDE4A (0.88) | KMT2APDE4AMEN1CHRM1PDE4D | |
| SCHEMBL5424919 | 0.94 | PDE4A (0.88) | KMT2APDE4AMEN1CHRM1PDE4D | |
| SCHEMBL5425481 | 0.94 | PDE4A (0.88) | KMT2APDE4AMEN1CHRM1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2380 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250275979-A1 | TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2025-09-04 | — | — | US | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2024211746-A1 | TREATMENT OF AUTOIMMUNE DISEASES AND CANCER WITH PROTEASE INHIBITORS | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2024-10-10 | — | — | WO | claimed |
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2024-10-03 | — | — | US | claimed |
| US-20240207233-A1 | MEDICAMENT | KOWA COMPANY, LTD. (JP) | 2024-06-27 | — | — | US | claimed |
| EP-4370128-A1 | TREATMENT OF INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2024-05-22 | — | — | EP | claimed |
| EP-4337208-A1 | VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH A CYP3A INHIBITOR AND AZACITIDINE | AbbVie Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| US-20240000810-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS | Orcosa Inc. (US) | 2024-01-04 | — | — | US | claimed |
| WO-2002006826-A1 | SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE | OPT-E-SCRIP, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| EP-1124556-A1 | USE OF OPTICALLY PURE (R)-TOFISOPAM FOR TREATING AND PREVENTING ANXIETY DISORDERS AND COMPOSITION THEREOF | Vela Pharmaceuticals Inc. (US) | 2001-08-22 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-6080736-A | TREAT OR PREVENT ANXIETY OR ANXIETY DISORDERS EITHER ALONE OR IN CONJUNCTION WITH PSYCHOTHERAPY AND/OR ANTIDEPRESSANTS | JANUS PHARMACEUTICALS, INC. (US) | 2000-06-27 | — | — | US | claimed |
| WO-2000024400-A1 | USE OF OPTICALLY PURE (R)-TOFISOPAM FOR TREATING AND PREVENTING ANXIETY DISORDERS AND COMPOSITION THEREOF | VELA PHARMACEUTICALS INC. (US) | 2000-05-04 | — | — | WO | claimed |
| WO-2000020005-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AN OPIATE ANALGESIC AND A SYNERGIZING SUBSTANCE | EGIS Gyógyszergyár Rt. (HU) | 2000-04-13 | — | — | WO | claimed |
| WO-1999004797-A1 | USE OF 2,3-BENZODIAZEPINE DERIVATIVES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO TREAT DISEASES CONNECTED WITH THE ENDOGENOUS OPIOID SYSTEM | EGIS Gyógyszergyár Rt. (HU) | 1999-02-04 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |